Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 5Nivolumab 4trametinib 2relatlimab 2larotrectinib 2dabrafenib 2cemiplimab 2binimetinib 2Vemurafenib 2Ipilimumab 2ulixertinib 1trastuzumab biosimilar HLX02 1sapanisertib 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1mogamulizumab 1ipatasertib 1erdafitinib 1entrectinib 1encorafenib 1defactinib 1copanlisib 1cobimetinib 1capivasertib 1atezolizumab 1adavosertib 1X-Rays 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Vorinostat × Dermatologic × Clear all
NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Kyowa Kirin Co., Ltd.

Phase 3 Completed
372 enrolled 14 charts 1 FDA
DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡